Novo Nordisk says experimental drug amycretin show 13% weight loss in trial
Reuters was first to report on the early trial data for Novo Nordisk’s highly anticipated experimental drug amycretin which showed […] The post Novo Nordisk says experimental drug amycretin show 13% weight loss in trial appeared first on Reuters News Agency.
Reuters was first to report on the early trial data for Novo Nordisk’s highly anticipated experimental drug amycretin which showed that participants had a weight loss of 13.1% after 12 weeks, prompting the company’s shares to rise to record highs and placing it above Tesla by market valuation.
The post Novo Nordisk says experimental drug amycretin show 13% weight loss in trial appeared first on Reuters News Agency.
What's Your Reaction?
.gif)